F.D.A. Clears New Cancer-Fighting Drug From Roche

.

F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.


Latest News

Ford Shares Drop With Profit Concerns
Dominion LNG Export Project Gets Green Signal from FERC
Second Quarter Shows Fastest Growth of U.S Economy
Stronger Safeguarding Rules for Service Members Against Predatory Lenders
Yahoo Urged to Buy Rival AOL Inc.
Slowing Down of Inflation May Make it Difficult for BOJ to Achieve its Target
B.K. Modi’s CIO Plans to Start Pre-IPO Fund
American Soda makers Promise to Trim Twenty Percent Calories by 2025
Federal Reserve Bank of Dallas has Hired a Search Firm to Find Suitable Replacem
Stricter Rules on Tax Inversion Push Down Stocks of Firms Considering Such Moves
Brazilian President Says Growth in the U.S. Could Result in an Improvement of Br
Anonymous Whistleblower to get $30 Million from SEC